GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (CHIX:AMGd) » Definitions » Cyclically Adjusted PB Ratio

Amgen (CHIX:AMGD) Cyclically Adjusted PB Ratio : 10.42 (As of Jun. 23, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Amgen Cyclically Adjusted PB Ratio?

As of today (2025-06-23), Amgen's current share price is €251.60. Amgen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €24.14. Amgen's Cyclically Adjusted PB Ratio for today is 10.42.

The historical rank and industry rank for Amgen's Cyclically Adjusted PB Ratio or its related term are showing as below:

CHIX:AMGd' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.86   Med: 7.09   Max: 12.02
Current: 10.92

During the past years, Amgen's highest Cyclically Adjusted PB Ratio was 12.02. The lowest was 4.86. And the median was 7.09.

CHIX:AMGd's Cyclically Adjusted PB Ratio is ranked worse than
93.72% of 749 companies
in the Drug Manufacturers industry
Industry Median: 1.98 vs CHIX:AMGd: 10.92

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Amgen's adjusted book value per share data for the three months ended in Mar. 2025 was €10.679. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €24.14 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Amgen Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Amgen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Cyclically Adjusted PB Ratio Chart

Amgen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.40 7.15 8.54 9.82 9.65

Amgen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.76 10.96 11.57 9.65 11.76

Competitive Comparison of Amgen's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted PB Ratio falls into.


;
;

Amgen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Amgen's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=251.60/24.14
=10.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Amgen's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=10.679/134.9266*134.9266
=10.679

Current CPI (Mar. 2025) = 134.9266.

Amgen Quarterly Data

Book Value per Share CPI Adj_Book
201506 32.260 100.684 43.232
201509 33.009 100.392 44.364
201512 34.191 99.792 46.229
201603 34.282 100.470 46.039
201606 35.810 101.688 47.515
201609 36.814 101.861 48.764
201612 38.376 101.863 50.833
201703 38.915 102.862 51.046
201706 38.638 103.349 50.444
201709 37.215 104.136 48.219
201712 29.533 104.011 38.311
201803 19.009 105.290 24.360
201806 19.664 106.317 24.956
201809 19.199 106.507 24.322
201812 17.452 105.998 22.215
201903 15.603 107.251 19.629
201906 15.866 108.070 19.809
201909 16.642 108.329 20.728
201912 14.720 108.420 18.319
202003 14.599 108.902 18.088
202006 16.141 108.767 20.023
202009 15.945 109.815 19.591
202012 13.374 109.897 16.420
202103 13.629 111.754 16.455
202106 12.017 114.631 14.145
202109 12.362 115.734 14.412
202112 10.621 117.630 12.183
202203 1.557 121.301 1.732
202206 4.278 125.017 4.617
202209 6.916 125.227 7.452
202212 6.472 125.222 6.974
202303 9.349 127.348 9.905
202306 11.701 128.729 12.264
202309 13.406 129.860 13.929
202312 10.674 129.419 11.128
202403 8.621 131.776 8.827
202406 10.250 132.554 10.433
202409 12.617 133.029 12.797
202412 10.452 133.157 10.591
202503 10.679 134.927 10.679

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Amgen  (CHIX:AMGd) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Amgen Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Amgen's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen Business Description

Industry
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Headlines

No Headlines